ATP-mediated kinome selectivity: the missing link in understanding the contribution of individual JAK Kinase isoforms to cellular signaling.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  ACS Chemical Biology

• Publication date

  2014-05-28

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1021/cb5002125PMID 24814050
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A public-private partnership to unlock the untargeted kinome.

  2013cited by this paper
• 3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models.

  2013cited by this paper
• Differential selectivity of JAK2 inhibitors in enzymatic and cellular settings.

  2013cited by this paper
• Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 – 2012

  2013cited by this paper
• Kinase drug discovery--what's next in the field?

  2013cited by this paper
• Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.

  2012cited by this paper
• JAK Kinases in Health and Disease: An Update

  2012cited by this paper
• Janex-1, a JAK3 inhibitor, ameliorates tumor necrosis factor-α-induced expression of cell adhesion molecules and improves myocardial vascular permeability in endotoxemic mice.

  2012cited by this paper
• Targeting Janus tyrosine kinase 3 (JAK3) with an inhibitor induces secretion of TGF-β by CD4+ T cells

  2012cited by this paper
• Selective JAK1 inhibitor and selective Tyk2 inhibitor patents

  2012cited by this paper
• Covalent inhibitors of interleukin-2 inducible T cell kinase (itk) with nanomolar potency in a whole-blood assay.

  2012cited by this paper
• The use of structural biology in Janus kinase targeted drug discovery.

  2011cited by this paper
• Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity

  2011cited by this paper
• Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors.

  2011cited by this paper
• The evolution of protein kinase inhibitors from antagonists to agonists of cellular signaling.

  2011cited by this paper
• Comprehensive analysis of kinase inhibitor selectivity

  2011cited by this paper
• Trends in kinase selectivity: insights for target class-focused library screening.

  2011cited by this paper
• Identification of a potent Janus kinase 3 inhibitor with high selectivity within the Janus kinase family.

  2011cited by this paper
• Analysis of kinase inhibitor selectivity using a thermodynamics-based partition index.

  2010cited by this paper
• Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice.

  2010cited by this paper
• Small kinase assay panels can provide a measure of selectivity.

  2009cited by this paper
• Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition

  2008cited by this paper
• Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition

  2008cited by this paper
• Gini coefficient: a new way to express selectivity of kinase inhibitors against a family of kinases.

  2007cited by this paper
• Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2).

  2007cited by this paper
• Features of selective kinase inhibitors.

  2005cited by this paper
• The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding.

  1998cited by this paper
• Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

  1973cited by this paper

• Identification of 2,4-Diaminopyrimidine Derivatives as Novel Gut-Restricted Selective JAK1 Inhibitors for the Treatment of Inflammatory Bowel Disease.

  2026cites this paper
• Interindividual variability and its impact on the effectiveness of Janus kinase inhibitors in rheumatoid arthritis treatment

  2025cites this paper
• Harnessing tyrosine kinase 2: Breakthroughs in autoimmune disease and cancer therapy.

  2025cites this paper
• Rhodium-Catalyzed Homogeneous Asymmetric Hydrogenation of Naphthylamine Derivatives.

  2025cites this paper
• Rhodium-Catalyzed Homogeneous Asymmetric Hydrogenation of Naphthol Derivatives.

  2025cites this paper
• JAK inhibitor selectivity: new opportunities, better drugs?

  2024cites this paper
• Intracellular ATP Levels: Challenge to the Current Consensus and Its Implications for Intracellular Signaling

  2024cites this paper
• Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor for the Treatment of Autoimmune Diseases

  2024cites this paper
• Discovery of the Potent and Selective Inhaled Janus Kinase 1 Inhibitor AZD4604 and Its Preclinical Characterization.

  2023cites this paper
• Quantification of Binding of Small Molecules to Native Proteins Overexpressed in Living Cells.

  2023cites this paper
• Differences in JAK Isoform Selectivity Among Different Types of JAK Inhibitors Evaluated for Rheumatic Diseases Through In Vitro Profiling

  2023cites this paper
• Discovery of Hexahydrofuro[3,2-b]furans as New Kinase-Selective and Orally Bioavailable JAK3 Inhibitors for the Treatment of Leukemia Harboring a JAK3 Activating Mutant.

  2022cites this paper
• Optimization of Pyrimidine Compounds as Potent JAK1 Inhibitors and the Discovery of R507 as a Clinical Candidate.

  2022cites this paper
• Elucidating the path to Plasmodium prolyl-tRNA synthetase inhibitors that overcome halofuginone resistance

  2022cites this paper
• After 25 years of drug development, do we know JAK?

  2022cites this paper
• Reducing False Positives through the Application of Fluorescence Lifetime Technology: A Comparative Study Using TYK2 Kinase as a Model System

  2021cites this paper
• Discovery of 3-(4-(2-((1H-Indol-5-yl)amino)-5-fluoropyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile Derivatives as Selective TYK2 Inhibitors for the Treatment of Inflammatory Bowel Disease.

  2021cites this paper
• Comparison of Janus kinase inhibitors to block the type I interferon pathway in human skeletal muscle cells

  2021cites this paper
• JAK Family Inhibitors for Autoimmune Diseases

  2021cites this paper
• Covalent drugs in development for immune-mediated diseases

  2021cites this paper
• Generation of a chemical genetic model for JAK3

  2021cites this paper
• Demonstration of In Vitro to In Vivo Translation of a TYK2 Inhibitor That Shows Cross Species Potency Differences

  2020cites this paper
• Covalent Janus Kinase 3 Inhibitors

  2020cites this paper
• Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1.

  2020cites this paper
• Hi-JAK-ing the ubiquitin system: The design and physicochemical optimisation of JAK PROTACs.

  2020cites this paper
• The advantages of describing covalent inhibitor in vitro potencies by IC50 at a fixed time point. IC50 determination of covalent inhibitors provides meaningful data to medicinal chemistry for SAR optimization.

  2020cites this paper
• Discovery of a Janus Kinase Inhibitor Bearing a Highly Three-Dimensional Spiro Scaffold: JTE-052 (Delgocitinib) as a New Dermatological Agent to Treat Inflammatory Skin Disorders.

  2020cites this paper
• Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition

  2019cites this paper
• Discovery of an Orally Available Janus Kinase 3 Selective Covalent Inhibitor.

  2019cites this paper
• Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid Arthritis.

  2019cites this paper
• Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) inhibitors.

  2019cites this paper
• High-Throughput Implementation of the NanoBRET Target Engagement Intracellular Kinase Assay to Reveal Differential Compound Engagement by SIK2/3 Isoforms

  2019cites this paper
• Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthma

  2018cites this paper
• Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.

  2018cites this paper
• Development, Optimization, and Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4- d]pyrrolo[2,3- b]pyridine Scaffold.

  2018cites this paper
• Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances.

  2018cites this paper
• Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841).

  2018cites this paper
• A Dual Inhibition, a Better Solution: Development of a JAK1/TYK2 inhibitor.

  2018cites this paper
• Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors.

  2018cites this paper
• Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor

  2017cites this paper
• Demonstrating In-Cell Target Engagement Using a Pirin Protein Degradation Probe (CCT367766)

  2017cites this paper
• Design and Synthesis of a Pan-Janus Kinase Inhibitor Clinical Candidate (PF-06263276) Suitable for Inhaled and Topical Delivery for the Treatment of Inflammatory Diseases of the Lungs and Skin.

  2017cites this paper
• Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting.

  2017cites this paper
• Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans.

  2017cites this paper
• Prediction of intracellular exposure bridges the gap between target- and cell-based drug discovery

  2017cites this paper
• Non-kinase targets of protein kinase inhibitors

  2017cites this paper
• Novel JAK1-selective benzimidazole inhibitors with enhanced membrane permeability.

  2016cites this paper
• Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition.

  2016cites this paper
• The Selective JAK1/3-Inhibitor R507 Mitigates Obliterative Airway Disease Both With Systemic Administration and Aerosol Inhalation

  2016cites this paper
• Phosphoproteome Analysis of Invasion and Metastasis-Related Factors in Pancreatic Cancer Cells

  2016cites this paper
• The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase.

  2016cites this paper
• Characterization of the catalytic CK2 subunits with substitutions at residues involved in inhibitor binding

  2016cites this paper
• Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket

  2016cites this paper
• Tofacitinib (Xeljanz): The First‐in‐Class JAK Inhibitor for the Treatment of Rheumatoid Arthritis

  2015cites this paper
• Know your target, know your molecule.

  2015cites this paper
• Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders.

  2015cites this paper
• Progress toward JAK1-selective inhibitors.

  2015cites this paper
• Benzimidazole Derivatives as Potent JAK1-Selective Inhibitors.

  2015cites this paper
• Selective inhibitors of the Janus kinase Jak3--Are they effective?

  2014cites this paper
• Chapter Twenty-Five - Case History: Xeljanz™ (Tofacitinib Citrate), a First-in-Class Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis

  2014cites this paper